Autolus director files initial insider holdings
Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company. The filing shows multiple share option awards over American Depositary Shares with exercise prices from $0.001 to $30.29 and expiration dates extending through 2036.
He also reports 50,000 restricted share units that vest in four equal annual installments starting on January 26, 2027, with each unit convertible into one American Depositary Share. In addition, he holds 70,000 American Depositary Shares directly. The filing records holdings only and does not reflect new market purchases or sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Share Option (right to buy) | -- | -- | -- |
| Holding | Restricted Share Units | -- | -- | -- |
| Holding | American Depositary Shares | -- | -- | -- |
Footnotes (8)
- F1. Fully vested and exercisable.
- F2. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter.
- F3. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F4. This option vests 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F5. This option vests 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.
- F6. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.
- F7. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.
- F8. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Autolus Therapeutics (AUTL) Form 3 filing disclose?
What stock options does Martin Anton Pule hold in Autolus (AUTL)?
AI-generated analysis. How Rhea-AI works. Not financial advice.
